Northern Trust’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-62,134
| Closed | -$124K | – | 4481 |
|
|
2025
Q2 | $124K | Sell |
62,134
-164,395
| -73% | -$301K | ﹤0.01% | 4064 |
|
|
2025
Q1 | $328K | Sell |
226,529
-23,081
| -9% | -$42.7K | ﹤0.01% | 3754 |
|
|
2024
Q4 | $517K | Buy |
249,610
+6,916
| +3% | +$13K | ﹤0.01% | 3647 |
|
|
2024
Q3 | $427K | Buy |
242,694
+5,403
| +2% | +$13.9K | ﹤0.01% | 3616 |
|
|
2024
Q2 | $3.43M | Sell |
237,291
-6,657
| -3% | -$91.5K | ﹤0.01% | 2606 |
|
|
2024
Q1 | $4.06M | Sell |
243,948
-3,725
| -2% | -$59.6K | ﹤0.01% | 2592 |
|
|
2023
Q4 | $3.98M | Buy |
247,673
+75,422
| +44% | +$1M | ﹤0.01% | 2635 |
|
|
2023
Q3 | $2.32M | Buy |
172,251
+11,120
| +7% | +$157K | ﹤0.01% | 2861 |
|
|
2023
Q2 | $2.77M | Buy |
161,131
+28,116
| +21% | +$436K | ﹤0.01% | 2819 |
|
|
2023
Q1 | $2.2M | Sell |
133,015
-3,957
| -3% | -$63.3K | ﹤0.01% | 2897 |
|
|
2022
Q4 | $2.29M | Buy |
136,972
+33,392
| +32% | +$603K | ﹤0.01% | 2930 |
|
|
2022
Q3 | $1.77M | Sell |
103,580
-1,165
| -1% | -$16.9K | ﹤0.01% | 3080 |
|
|
2022
Q2 | $1.15M | Buy |
+104,745
| New | +$1.24M | ﹤0.01% | 3309 |
|
Northern Trust's HLVX Position: Q3 2025 in Review
Northern Trust sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 62,134 shares — an estimated $124K sold.
Northern Trust first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $4.06M in Q1 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Northern Trust reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Northern Trust sold 62,134 HilleVax shares in Q3 2025, an estimated $124K.
- Northern Trust first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Northern Trust's HilleVax position peaked at $4.06M in Q1 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Northern Trust's 13F filing for Q3 2025, filed 14 Nov 2025.